{"id":"tca-ir-40","safety":{"commonSideEffects":[{"rate":"null","effect":"Numbness"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by inhibiting the sodium channels in nerve cells, which prevents the transmission of pain signals to the brain. This results in a temporary loss of sensation in the affected area.","oneSentence":"TCA IR 40 is a local anesthetic that works by blocking nerve signals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:38.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative pain management"}]},"trialDetails":[{"nctId":"NCT06478186","phase":"PHASE4","title":"Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2024-08-16","conditions":"Osteoarthritis, Knee, Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT02357459","phase":"PHASE3","title":"Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2015-01","conditions":"Osteoarthritis of the Knee","enrollment":486},{"nctId":"NCT01487161","phase":"PHASE2","title":"Study of FX006 in Patients With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2012-06","conditions":"Osteoarthritis of the Knee","enrollment":229},{"nctId":"NCT01487200","phase":"PHASE2","title":"Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2012-07","conditions":"Osteoarthritis of the Knee","enrollment":24},{"nctId":"NCT03382262","phase":"PHASE2","title":"Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2017-12-18","conditions":"Osteoarthritis of the Shoulder, Osteoarthritis of the Hip","enrollment":55},{"nctId":"NCT02003365","phase":"PHASE2","title":"Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2013-11","conditions":"Osteoarthritis of the Knee","enrollment":50},{"nctId":"NCT02762370","phase":"PHASE2","title":"Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2016-04","conditions":"Osteoarthritis of the Knee, Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT02468583","phase":"PHASE2","title":"Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee","status":"TERMINATED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2015-02","conditions":"Post-traumatic Osteoarthritis of the Knee","enrollment":6},{"nctId":"NCT03378076","phase":"PHASE2","title":"Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2017-12-06","conditions":"Bilateral Knee Osteoarthritis","enrollment":24},{"nctId":"NCT02637323","phase":"PHASE2","title":"Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee","status":"COMPLETED","sponsor":"Pacira Pharmaceuticals, Inc","startDate":"2015-11","conditions":"Osteoarthritis of the Knee","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kenalog®-40","Kenacort-A 40","Triamcinolone Acetonide Crystalline Suspension (TAcs)","Kenalog®-40 Injection"],"phase":"phase_3","status":"active","brandName":"TCA IR 40","genericName":"TCA IR 40","companyName":"Pacira Pharmaceuticals, Inc","companyId":"pacira-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TCA IR 40 is a local anesthetic that works by blocking nerve signals. Used for Postoperative pain management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}